Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which progesterone works best for menopause? new study aims to find out

NCT ID NCT07496294

Symptom relief Sponsor: Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two common progesterone treatments (oral dydrogesterone vs. vaginal micronized progesterone) for women going through menopause. All 200 participants will use an estradiol gel and be randomly assigned to one of the two progesterone options. The goal is to see which one better relieves symptoms like hot flashes and night sweats while keeping the uterus healthy. Results may help doctors choose the best hormone therapy for each woman.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 60 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged 45-60 years * Postmenopausal status (absence of menstruation for ≥12 months) * Intact uterus * Presence of menopausal symptoms requiring menopausal hormone therapy * Willingness to participate and provide written informed consent Exclusion Criteria: * Unexplained vaginal bleeding * History of breast cancer or endometrial cancer * Known hypersensitivity to study medications * History of thromboembolic disease (e.g., deep vein thrombosis or pulmonary embolism) * Severe liver disease * Uncontrolled hypertension * Any condition that, in the opinion of the investigator, makes participation inappropriate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hormone therapy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hormone therapy Menopausal hormone therapy Menopausal symptom relief Menopausal women

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sancaktepe Sehit Prof. Dr. Ilhan Varank Training and Research Hospital

    Istanbul, 34785, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.